Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
Background: Many European countries introduced (confidential) rebates in the past years. Authorities and manufacturers argue that this strategy allows reduction of spending on high-cost drugs, and quick access of innovative drugs. We evaluated these arguments using Switzerland as an example, one of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | The Lancet Regional Health. Europe |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776221000272 |